Navigation Links
Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
Date:11/21/2008

atological malignancy or Myelodysplastic Syndrome (MDS). Nplate is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

In the U.S. Nplate is available only through a restricted distribution program called Nplate(TM) NEXUS (Network of Experts Understanding and Supporting Nplate and Patients) Program.

In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disorder, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statement

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, re
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Life Recovery Systems Receives NIH Grant to Study Expanded Use of Its ThermoSuit System
5. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
6. Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
7. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
10. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
11. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... DURECT Corporation (Nasdaq: DRRX ) announced today that it has secured a ... million of its registered common stock to Azimuth Opportunity Ltd. for a ... $50 million facility.  DURECT did not pay a commitment fee or ... , , ...
... WASHINGTON , July 1 Hanger Orthopedic ... efforts in response to the January 12th ... alliance of U.S.-based international development and humanitarian nongovernmental organizations. ... Orthopedic Group was nominated by Physicians for Peace, an ...
Cached Medicine Technology:DURECT Corporation Secures $50 Million Committed Equity Financing Facility 2DURECT Corporation Secures $50 Million Committed Equity Financing Facility 3Hanger Orthopedic Group Honored for its Charitable Relief Efforts in Haiti by InterAction 2Hanger Orthopedic Group Honored for its Charitable Relief Efforts in Haiti by InterAction 3
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... particles for treatment of diseases. ‘Nano’ refers to billionth ... for treatment of fatal diseases, which will help to ... to develop Nanotechnology in the next 10 years which ... diabetes, Cancer, HIV infection, Alzheimer’s and Parkinson’s diseases. Six ...
... at UCLA had found out the peptides that ward ... more than 20 years ago at UCLA, defensins are ... ward off viruses. However, it was unclear how defensins ... a specific defensin called retrocyclin-2 (RC2) binds to carbohydrate-containing ...
... no sunscreen in spite of staying under direct sunlight for ... spend a significant amount of time practicing and competing in ... are spending so much time in the sun, they have ... them regularly use any form of sunscreen, according to a ...
... that are difficult to handle. Even when so much has ... viral infection has always been a problem. Viral infections ... the disease-causing virus has always been potent enough to escape ... Human Immunodeficiency Virus as it is called has been posing ...
... Immunization (IFFIm) will be providing life saving vaccines for ... project costing $4 billion to be funded by the ... the scheme, the International Finance Facility for Immunization (IFF), ... over the next 10 years and another five million ...
... and Rabia Khatoon's joy knew no bounds when they got ... to pay for the surgery to separate their conjoined twins.// ... thousands of miles away has offered to help us,' Khatoon, ... even as the children get medical attention at New Delhi's ...
Cached Medicine News:Health News:Nanotechnology Revolution To Be Spearheaded By European Union 2Health News:People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings 2Health News:European Countries To Fund $4 Billion For Vaccination For Poor Children’ 2Health News:When A Prince Chose To Help Indian Couple 2
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... Guidants 20-year history, the VOYAGER RX Dilatation ... treatment outcomes. It combines a new low ... profile shaft,more flexible markers, and short taper ... and tortuous anatomy with even greater confidence, ...
... Coat-A-Count AFP IRMA,is an ... measurement of,alpha-fetoprotein (AFP) in serum. ... vitro use in either of,two ... aid in the,management of patients ...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
Medicine Products: